Response of Normal Tissues to Boron Neutron Capture Therapy (BNCT) with <sup>10</sup>B-Borocaptate Sodium (BSH) and <sup>10</sup>B-Paraboronophenylalanine (BPA)
Boron neutron capture therapy (BNCT) is a cancer-selective radiotherapy that utilizes the cancer targeting <sup>10</sup>B-compound. Cancer cells that take up the compound are substantially damaged by the high liner energy transfer (LET) particles emitted mainly from the <sup>10<...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/11/2883 |
| _version_ | 1797510845446488064 |
|---|---|
| author | Hiroshi Fukuda |
| author_facet | Hiroshi Fukuda |
| author_sort | Hiroshi Fukuda |
| collection | DOAJ |
| description | Boron neutron capture therapy (BNCT) is a cancer-selective radiotherapy that utilizes the cancer targeting <sup>10</sup>B-compound. Cancer cells that take up the compound are substantially damaged by the high liner energy transfer (LET) particles emitted mainly from the <sup>10</sup>B(n, α<sup>7</sup>Li reaction. BNCT can minimize the dose to normal tissues, but it must be performed within the tolerable range of normal tissues. Therefore, it is important to evaluate the response of normal tissues to BNCT. Since BNCT yields a mixture of high and low LET radiations that make it difficult to understand the radiobiological basis of BNCT, it is important to evaluate the relative biological effectiveness (RBE) and compound biological effectiveness (CBE) factors for assessing the responses of normal tissues to BNCT. BSH and BPA are the only <sup>10</sup>B-compounds that can be used for clinical BNCT. Their biological behavior and cancer targeting mechanisms are different; therefore, they affect the CBE values differently. In this review, we present the RBE and CBE values of BPA or BSH for normal tissue damage by BNCT irradiation. The skin, brain (spinal cord), mucosa, lung, and liver are included as normal tissues. The CBE values of BPA and BSH for tumor control are also discussed. |
| first_indexed | 2024-03-10T05:37:06Z |
| format | Article |
| id | doaj.art-242afb52f4eb4a05a5e7dd73eca2140d |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T05:37:06Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-242afb52f4eb4a05a5e7dd73eca2140d2023-11-22T22:48:08ZengMDPI AGCells2073-44092021-10-011011288310.3390/cells10112883Response of Normal Tissues to Boron Neutron Capture Therapy (BNCT) with <sup>10</sup>B-Borocaptate Sodium (BSH) and <sup>10</sup>B-Paraboronophenylalanine (BPA)Hiroshi Fukuda0Department of Radiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, JapanBoron neutron capture therapy (BNCT) is a cancer-selective radiotherapy that utilizes the cancer targeting <sup>10</sup>B-compound. Cancer cells that take up the compound are substantially damaged by the high liner energy transfer (LET) particles emitted mainly from the <sup>10</sup>B(n, α<sup>7</sup>Li reaction. BNCT can minimize the dose to normal tissues, but it must be performed within the tolerable range of normal tissues. Therefore, it is important to evaluate the response of normal tissues to BNCT. Since BNCT yields a mixture of high and low LET radiations that make it difficult to understand the radiobiological basis of BNCT, it is important to evaluate the relative biological effectiveness (RBE) and compound biological effectiveness (CBE) factors for assessing the responses of normal tissues to BNCT. BSH and BPA are the only <sup>10</sup>B-compounds that can be used for clinical BNCT. Their biological behavior and cancer targeting mechanisms are different; therefore, they affect the CBE values differently. In this review, we present the RBE and CBE values of BPA or BSH for normal tissue damage by BNCT irradiation. The skin, brain (spinal cord), mucosa, lung, and liver are included as normal tissues. The CBE values of BPA and BSH for tumor control are also discussed.https://www.mdpi.com/2073-4409/10/11/2883BNCTnormal tissue damageBSHBPARBECBE |
| spellingShingle | Hiroshi Fukuda Response of Normal Tissues to Boron Neutron Capture Therapy (BNCT) with <sup>10</sup>B-Borocaptate Sodium (BSH) and <sup>10</sup>B-Paraboronophenylalanine (BPA) Cells BNCT normal tissue damage BSH BPA RBE CBE |
| title | Response of Normal Tissues to Boron Neutron Capture Therapy (BNCT) with <sup>10</sup>B-Borocaptate Sodium (BSH) and <sup>10</sup>B-Paraboronophenylalanine (BPA) |
| title_full | Response of Normal Tissues to Boron Neutron Capture Therapy (BNCT) with <sup>10</sup>B-Borocaptate Sodium (BSH) and <sup>10</sup>B-Paraboronophenylalanine (BPA) |
| title_fullStr | Response of Normal Tissues to Boron Neutron Capture Therapy (BNCT) with <sup>10</sup>B-Borocaptate Sodium (BSH) and <sup>10</sup>B-Paraboronophenylalanine (BPA) |
| title_full_unstemmed | Response of Normal Tissues to Boron Neutron Capture Therapy (BNCT) with <sup>10</sup>B-Borocaptate Sodium (BSH) and <sup>10</sup>B-Paraboronophenylalanine (BPA) |
| title_short | Response of Normal Tissues to Boron Neutron Capture Therapy (BNCT) with <sup>10</sup>B-Borocaptate Sodium (BSH) and <sup>10</sup>B-Paraboronophenylalanine (BPA) |
| title_sort | response of normal tissues to boron neutron capture therapy bnct with sup 10 sup b borocaptate sodium bsh and sup 10 sup b paraboronophenylalanine bpa |
| topic | BNCT normal tissue damage BSH BPA RBE CBE |
| url | https://www.mdpi.com/2073-4409/10/11/2883 |
| work_keys_str_mv | AT hiroshifukuda responseofnormaltissuestoboronneutroncapturetherapybnctwithsup10supbborocaptatesodiumbshandsup10supbparaboronophenylalaninebpa |